🌟 Alpesib 150 mg (Alpelisib) – Everest Pharma

Alpesib 150 mg contains Alpelisib, a selective PI3K-alpha inhibitor developed to provide targeted therapy for patients with specific genetic mutations associated with advanced breast cancer. Alpesib represents a significant advancement in personalized oncology care, aiming to inhibit cancer cell growth driven by PIK3CA mutations.

💊 Composition

Each film-coated tablet contains:
👉 Alpelisib 150 mg

⚡ Indications

Alpesib 150 mg is indicated for the treatment of:

• HR-positive, HER2-negative advanced or metastatic breast cancer

• In adult patients whose tumors have a PIK3CA mutation, as detected by an approved test

• Typically administered in combination with fulvestrant after progression on or after endocrine-based therapy

📌 Key Features

✅ Selective inhibition of PI3K-alpha isoform, targeting tumor cell proliferation
✅ Personalized therapy based on tumor genetic profile
✅ Oral once-daily tablet for convenient administration
✅ Manufactured by Everest Pharmaceuticals Ltd., delivering high-quality, affordable targeted therapies

📌 Category:

➡️ Oncology / Anti-cancer Medicine
➡️ Targeted Therapy / Precision Medicine
➡️ PI3K Inhibitor (Phosphatidylinositol-3-kinase inhibitor)

---

🧬 Therapeutic Class:

• Selective PI3K-alpha isoform inhibitor

• Molecular targeted agent for solid tumors

---

💡 Indication-specific Category:

• Targeted therapy for HR-positive, HER2-negative, PIK3CA-mutated advanced breast cancer

• Oral targeted anti-cancer agent

🕒 Dosage & Administration

• Recommended dose: 300 mg once daily (as two 150 mg tablets) taken orally

• Should be taken immediately after a meal for optimal absorption

• Dose modifications may be required based on tolerability

🏭 Manufacturer

Everest Pharmaceuticals Ltd.
A leading provider of innovative, cost-effective oncology medicines for global cancer care.

🚀 Why Choose Alpesib?

Alpesib 150 mg (Alpelisib) empowers oncologists with a precision medicine option for managing advanced breast cancer with PIK3CA mutations. It combines cutting-edge science with patient-friendly dosing to support better outcomes.